Share your thoughts and join the conversation in the comments.

Cancer diagnostic firm Caris Life Sciences on Monday raised the proposed price range for its New York initial public offering, targeting a valuation of up to $5.67 billion and indicating a strong ...

GVA Capital hid $1.3B for Russian oligarch Kerimov despite US sanctions. OFAC’s $215.9M fine warns gatekeepers: close ...